Clinical characteristics and diagnostic challenges of patients with pulmonary actinomycosis: A 10-year experience at a tertiary referral hospital


Creative Commons License

SÖKÜCÜ S. N., Akyel R., Akyıl F. T., Önür S. T., Kara K., Veske N. Ş., ...Daha Fazla

Eurasian Journal of Pulmonology, cilt.26, sa.3, ss.173-179, 2024 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 3
  • Basım Tarihi: 2024
  • Doi Numarası: 10.14744/ejp.2024.1003
  • Dergi Adı: Eurasian Journal of Pulmonology
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.173-179
  • Anahtar Kelimeler: Bronchoscopy, lung cancer, positron emission tomography, pulmonary actinomycosis
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

BACKGROUND AND AIM: This study reviews the clinical characteristics, radiological findings, and diagnostic procedures for patients with pulmonary actinomycosis (PA). It also assesses the utility of18F-fluo-rodeoxyglucose positron emission tomography-computed tomography (PET-CT) scans in diagnosing PA. METHODS: Conducted retrospectively at a tertiary referral hospital, this study investigated patients diagnosed with PA between January 2012 and January 2022. Demographics, clinical and radiological findings at presentation, diagnostic steps, PET-CT findings, and the time interval to diagnosis were analyzed. RESULTS: Among the 34 patients, the mean age at diagnosis was 49 years (range 23−77), with 19 (56%) being male. The most common symptom was cough, reported by 23 patients (68%). Chronic obstructive pulmonary disease and bronchiectasis were the most frequent underlying conditions. Typical chest tomography features included nodular lesions, mass lesions, consolidation, bronchiec-tasis, and atelectasis. Initial pre-diagnoses included lung cancer in 16 patients (47%), tuberculosis in 9 patients (27%), and late-resolving pneumonia in 6 patients (18%). No patient received an accurate initial diagnosis of PA. All definitive diagnoses were made histopathologically through specimens obtained from: sputum analysis in 1 (2.9%) patient, flexible bronchoscopy in 17 (50%) patients, rigid bronchoscopy in 1 (2.9%) patient, endobronchial ultrasonography in 2 (5.9%) patients, transthorac-ic needle aspiration in 6 (17.7%) patients, and surgical resection in 7 (20.6%) patients. The mean time from symptom onset to definitive diagnosis was 53.2±44.1 days (Range 9−175 days). Among the patients, 16 (47%) underwent PET-CT, and 10 (29%) underwent cranial magnetic resonance imaging. From the re-assessment of 13 PET-CT scans, the derived values were as follows: Standard Uptake Value (SUV) max value was 6.98±2.74 (range 0.9−9.92), SUVmean value was 3.95±1.51 (range 0.51−5.30), SUVpeak value was 5.68±2.24 (range 0.64−7.89), tumor lesion glycolysis was 138.58±151.86 (range 3−440.5), and metabolic tumor volume was 27.85±37.97 (range 0−131.00). CONCLUSIONS: The diagnosis of PA is challenging and often delayed, frequently misdiagnosed as lung cancer or pulmonary tuberculosis. PA shows moderate metabolic uptake on PET-CT scans and, PET-CT scan is insufficient for accurate and timely differentiation between lung malignancy and PA.